NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Receives $8.50 Consensus Target Price from Brokerages

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) have received a consensus recommendation of “Moderate Buy” from the five ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $8.50.

Separately, Weiss Ratings downgraded shares of NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th.

Insider Activity

In related news, CFO Or Eisenberg acquired 250,000 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was acquired at an average price of $0.80 per share, with a total value of $200,000.00. Following the acquisition, the chief financial officer directly owned 1,504,050 shares in the company, valued at $1,203,240. This represents a 19.94% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Alon Ben-Noon bought 250,000 shares of the stock in a transaction dated Tuesday, June 16th. The stock was bought at an average price of $0.80 per share, for a total transaction of $200,000.00. Following the purchase, the chief executive officer directly owned 4,534,233 shares of the company’s stock, valued at approximately $3,627,386.40. The trade was a 5.84% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 27.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of NRSN. Two Sigma Investments LP purchased a new stake in NeuroSense Therapeutics in the 3rd quarter worth approximately $26,000. Jane Street Group LLC purchased a new position in shares of NeuroSense Therapeutics during the 2nd quarter valued at approximately $54,000. Squarepoint Ops LLC increased its holdings in shares of NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares in the last quarter. Finally, Yorkville Advisors Global LP acquired a new position in shares of NeuroSense Therapeutics in the 2nd quarter valued at $56,160,000. 1.04% of the stock is owned by institutional investors and hedge funds.

NeuroSense Therapeutics Trading Down 5.5%

NRSN opened at $0.44 on Friday. NeuroSense Therapeutics has a 12-month low of $0.39 and a 12-month high of $1.98. The firm has a 50 day moving average of $0.66 and a two-hundred day moving average of $0.77. The firm has a market capitalization of $16.74 million, a PE ratio of -0.82 and a beta of 1.62.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.